{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:05:48Z","timestamp":1790683548034,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,1,14]],"date-time":"2019-01-14T00:00:00Z","timestamp":1547424000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81473275"],"award-info":[{"award-number":["81473275"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Medical and Technology Intercrossing Research Foundation of Shanghai Jiaotong University","award":["YG2016MS60"],"award-info":[{"award-number":["YG2016MS60"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s00228-018-02613-w","type":"journal-article","created":{"date-parts":[[2019,1,14]],"date-time":"2019-01-14T10:03:54Z","timestamp":1547460234000},"page":"677-686","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Limited sampling strategy for the estimation of the area under the concentration-time curve for ganciclovir in Chinese adult renal allograft recipients"],"prefix":"10.1007","volume":"75","author":[{"given":"Wen-Bin","family":"Rui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Min","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Hui","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Qian","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan-Shan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4909-4792","authenticated-orcid":false,"given":"Bing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Jun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,14]]},"reference":[{"issue":"1","key":"2613_CR1","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/j.1523-1755.2004.00735.x","volume":"66","author":"S Sagedal","year":"2004","unstructured":"Sagedal S, Hartmann A, Nordal KP, Osnes K, Leivestad T, Foss A, Degr\u00e9 M, Fauchald P, Rollag H (2004) Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int 66(1):329\u2013337","journal-title":"Kidney Int"},{"key":"2613_CR2","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1097\/00007890-200010270-00007","volume":"70","author":"S Sagedal","year":"2000","unstructured":"Sagedal S, Nordal KP, Hartmann A et al (2000) A prospective study of the natural course of cytomegalovirus infection and disease in renal allograft recipients. Transplantation 70:1166\u20131174","journal-title":"Transplantation"},{"key":"2613_CR3","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1056\/NEJM199806113382407","volume":"338","author":"JA Fishman","year":"1998","unstructured":"Fishman JA, Rubin RH (1998) Infection in organ-transplant recipients. N Engl J Med 338:1741\u20131751","journal-title":"N Engl J Med"},{"key":"2613_CR4","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1007\/s00125-004-1499-z","volume":"47","author":"J Hjelmesaeth","year":"2004","unstructured":"Hjelmesaeth J, Sagedal S, Hartmann A et al (2004) Asymptomatic cytomegalovirus infection is associated with increased risk of new-onset diabetes mellitus and impaired insulin release after renal transplantation. Diabetologia 47:1550\u20131556","journal-title":"Diabetologia"},{"key":"2613_CR5","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1097\/01.TP.0000137105.92464.F3","volume":"78","author":"PC Nett","year":"2004","unstructured":"Nett PC, Heisey DM, Fernandez LA, Sollinger HW, Pirsch JD (2004) Association of cytomegalovirus disease and acute rejection with graft loss in kidney transplantation. Transplantation 78:1036\u20131041","journal-title":"Transplantation"},{"key":"2613_CR6","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1097\/00007890-199812270-00010","volume":"66","author":"HR Rosen","year":"1998","unstructured":"Rosen HR, Corless CL, Rabkin J, Chou S (1998) Association of cytomegalovirus genotype with graft rejection after liver transplantation. Transplantation 66:1627\u20131631","journal-title":"Transplantation"},{"key":"2613_CR7","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1034\/j.1600-6143.2002.20907.x","volume":"2","author":"S Sagedal","year":"2002","unstructured":"Sagedal S, Nordal KP, Hartmann A, Sund S, Scott H, Degre M, Foss A, Leivestad T, Osnes K, Fauchald P, Rollag H (2002) The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am J Transplant 2:850\u2013856","journal-title":"Am J Transplant"},{"key":"2613_CR8","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/j.1399-0012.2006.00639.x","volume":"21","author":"S Sagedal","year":"2007","unstructured":"Sagedal S, Rollag H, Hartmann A (2007) Cytomegalovirus infection in renal transplant recipients is associated with impaired survival irrespective of expected mortality risk. Clin Transpl 21:309\u2013313","journal-title":"Clin Transpl"},{"issue":"9","key":"2613_CR9","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1086\/508173","volume":"43","author":"SA Staras","year":"2006","unstructured":"Staras SA, Dollard SC, Radford KW et al (2006) Seroprevalence of cytomegalovirus infection in the United States, 1988-1994. Clin Infect Dis 43(9):1143\u20131151","journal-title":"Clin Infect Dis"},{"issue":"4","key":"2613_CR10","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1093\/infdis\/171.4.1002","volume":"171","author":"LJ Zhang","year":"1995","unstructured":"Zhang LJ, Hanff P, Rutherford C, Churchill WH, Crumpacker CS (1995) Detection of human cytomegalovirus DNA, RNA, and antibody in normal donor blood. J Infect Dis 171(4):1002\u20131006","journal-title":"J Infect Dis"},{"key":"2613_CR11","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1097\/TP.0b013e31829df29d","volume":"96","author":"CN Kotton","year":"2013","unstructured":"Kotton CN, Kumar D, Caliendo AM, \u00c5sberg A, Chou S, Danziger-Isakov L, Humar A (2013) Transplantation society international CMV consensus group: updated internationalconsensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 96:333\u2013360","journal-title":"Transplantation"},{"key":"2613_CR12","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1086\/319225","volume":"32","author":"N Singh","year":"2001","unstructured":"Singh N (2001) Preemptive therapy versus universal prophylaxis with ganciclovir for cytomegalovirus in solid organ transplant recipients. Clin Infect Dis 32:742\u2013751","journal-title":"Clin Infect Dis"},{"issue":"28","key":"2613_CR13","doi-asserted-by":"publisher","first-page":"25348","DOI":"10.1074\/jbc.M302055200","volume":"278","author":"I Kim","year":"2003","unstructured":"Kim I, Chu XY, Kim S, Provoda CJ, Lee KD, Amidon GL (2003) Identification of a human valacyclovirase: biphenyl hydrolaselike protein as valacyclovir hydrolase. Biol Chem 278(28):25348\u201325356","journal-title":"Biol Chem"},{"key":"2613_CR14","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1067\/mcp.2002.126306","volume":"72","author":"D Czock","year":"2002","unstructured":"Czock D, Scholle C, Rasche FM, Schaarschmidt D, Keller F (2002) Pharmacokinetics of valganciclovir and ganciclovir in renal impairment. Clin Pharmacol Ther 72:142\u2013150","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"2613_CR15","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1111\/j.1600-6143.2010.03074.x","volume":"10","author":"A Humar","year":"2010","unstructured":"Humar A, Lebranchu Y, Vincenti F, Blumberg EA, Punch JD, Limaye AP, Abramowicz D, Jardine AG, Voulgari AT, Ives J, Hauser IA, Peeters P (2010) The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 10(5):1228\u20131237","journal-title":"Am J Transplant"},{"issue":"12","key":"2613_CR16","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1097\/TP.0b013e3181ff1493","volume":"90","author":"A Humar","year":"2010","unstructured":"Humar A, Limaye AP, Blumberg EA, Hauser IA, Vincenti F, Jardine AG, Abramowicz D, Ives JAL, Farhan M, Peeters P (2010) Extended valganciclovir prophylaxis in D+\/R-kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease:two-year results of the IMPACT study. Transplantation 90(12):1427\u20131431","journal-title":"Transplantation"},{"key":"2613_CR17","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1097\/01.TP.0000164512.99703.AD","volume":"79","author":"H Wiltshire","year":"2005","unstructured":"Wiltshire H, Paya C, Pescovitz MD et al (2005) Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. Transplantation 79:1477\u20131483","journal-title":"Transplantation"},{"key":"2613_CR18","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1097\/FTD.0b013e3182509e3a","volume":"34","author":"W Zhao","year":"2012","unstructured":"Zhao W, Fakhoury M, Fila M, Baudouin V, Desch\u00eanes G, Jacqz-Aigrain E (2012) Individualization of valganciclovir prophylaxis for cytomegalovirus infection in pediatric kidney transplant patients. Valganciclovir pediatria. Ther Drug Monit 34:326\u2013330","journal-title":"Ther Drug Monit"},{"issue":"4","key":"2613_CR19","doi-asserted-by":"publisher","first-page":"311","DOI":"10.2165\/00003088-200039040-00006","volume":"39","author":"O David","year":"2000","unstructured":"David O, Johnston A (2000) Limited sampling strategies. Clin Pharmacokinet 39(4):311\u2013313","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"2613_CR20","doi-asserted-by":"publisher","first-page":"392","DOI":"10.5414\/CPP41392","volume":"41","author":"Mahmood","year":"2003","unstructured":"Mahmood (2003) Impact of random and fixed (optimal) sampling approach on the Bayesian estimation of clearance. Int J Clin Pharmacol Ther 41(9):392","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"3","key":"2613_CR21","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1097\/FTD.0000000000000007","volume":"36","author":"CA Padull\u00e9s","year":"2014","unstructured":"Padull\u00e9s CA, Colom H, Caldes A et al (2014) Optimal sparse sampling for estimating ganciclovir\/valganciclovir AUC in solid organ transplant patients using NONMEN. Ther Drug Monit 36(3):371\u2013377","journal-title":"Ther Drug Monit"},{"issue":"6","key":"2613_CR22","doi-asserted-by":"publisher","first-page":"399","DOI":"10.2165\/00003088-200948060-00006","volume":"48","author":"N Perrottet","year":"2009","unstructured":"Perrottet N, Laurent A, Decosterd et al (2009) Valganciclovir in adult solid organ transplant recipients: pharmacokinetic and pharmacodynamic characteristics and clinical interpretation of plasma concentration measurements. Clin Pharmacokinet 48(6):399\u2013418","journal-title":"Clin Pharmacokinet"},{"key":"2613_CR23","doi-asserted-by":"publisher","first-page":"495","DOI":"10.2165\/00003088-200544050-00003","volume":"44","author":"H Wiltshire","year":"2005","unstructured":"Wiltshire H, Hirankarn S, Farrell C, Paya C, Pescovitz MD, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, Freeman R, Heaton N (2005) The valganciclovir solid organ transplant study group. Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organtransplant recipients. Clin Pharmacokinet 44:495\u2013507","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"2613_CR24","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1111\/j.1600-6143.2008.02220.x","volume":"8","author":"CE Chamberlain","year":"2010","unstructured":"Chamberlain CE, Penzak SR, Alfaro RM et al (2010) Pharmacokinetics of low and maintenance dose valganciclovir in kidney transplant recipients. Am J Transplant 8(6):1297\u20131302","journal-title":"Am J Transplant"},{"issue":"14","key":"2613_CR25","doi-asserted-by":"publisher","first-page":"8039","DOI":"10.1073\/pnas.140123497","volume":"97","author":"VC Emery","year":"2000","unstructured":"Emery VC, Griffiths PD (2000) Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy. Proc Natl Acad Sci U S A 97(14):8039\u20138044","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9230","key":"2613_CR26","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/S0140-6736(00)02607-6","volume":"356","author":"AP Limaye","year":"2000","unstructured":"Limaye AP, Corey L, Koelle DM, Davis CL, Boeckh M (2000) Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 356(9230):645\u2013649","journal-title":"Lancet"},{"issue":"1","key":"2613_CR27","first-page":"1153","volume":"56","author":"JK Mcgavin","year":"1998","unstructured":"Mcgavin JK, Goa KL (1998) Ganciclovir: an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs 56(1):1153\u20131183","journal-title":"Drugs"},{"issue":"Supplement 3","key":"2613_CR28","doi-asserted-by":"publisher","first-page":"S507","DOI":"10.1093\/clinids\/10.Supplement_3.S507","volume":"3","author":"JP Sommadossi","year":"1988","unstructured":"Sommadossi JP, Bevan R, Ling T et al (1988) Clinical pharmacokinetics of ganciclovir in patients with normal and impaired renal function. Rev Infect Dis 3(Supplement 3):S507","journal-title":"Rev Infect Dis"},{"issue":"4","key":"2613_CR29","doi-asserted-by":"publisher","first-page":"597","DOI":"10.2165\/00003495-199039040-00008","volume":"39","author":"D Faulds","year":"1990","unstructured":"Faulds D, Heel RC (1990) Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infection. Drugs 39(4):597\u2013638","journal-title":"Drugs"},{"issue":"40","key":"2613_CR30","first-page":"2030","volume":"20","author":"E Rondeau","year":"1991","unstructured":"Rondeau E, Farquet C, Fries D et al (1991) Treatment of cytomegalovirus infections with ganciclovir in kidney transplant recipients. Clinical and pharmacokinetic study. Presse M\u00e9d 20(40):2030\u20132032","journal-title":"Presse M\u00e9d"},{"key":"2613_CR31","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/j.1875-9114.1997.tb03070.x","volume":"17","author":"EJ Wolfe","year":"1997","unstructured":"Wolfe EJ, Mathur V, Tomlanovich S et al (1997) Pharmacokinetics of mycophenolatemofetil and intravenous ganciclovir alone and in combination in renal transplant recipients. Pharmacotherapy 17:591\u2013598","journal-title":"Pharmacotherapy"},{"issue":"2","key":"2613_CR32","doi-asserted-by":"publisher","first-page":"167","DOI":"10.2165\/00003088-199937020-00005","volume":"37","author":"F Brown","year":"1999","unstructured":"Brown F, Banken L, Saywell K, Arum I (1999) Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive.Volunteers. Clin Pharmacokinet 37(2):167\u2013176","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"2613_CR33","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s004670050391","volume":"12","author":"G Filler","year":"1998","unstructured":"Filler G, Lampe D, von Bredow MA, Lappenberg-Pelzer M, Rocher S, Strehlau J, Ehrich JH (1998) Prophylactic oral ganciclovir after renal transplantation-dosing and pharmacokinetics. Pediatr Nephrol 12(1):6\u20139","journal-title":"Pediatr Nephrol"},{"key":"2613_CR34","first-page":"439","volume":"37","author":"I Mahmood","year":"1999","unstructured":"Mahmood I, Miller R (1999) Comparison of the Bayesian approach and a limited sampling model for the estimation of AUC and Cmax: a computer simulation analysis. Int J Clin Pharmacol Ther 37:439\u2013445","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"3","key":"2613_CR35","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1097\/01.ftd.0000211810.19935.44","volume":"28","author":"LS Ting","year":"2006","unstructured":"Ting LS, Villeneuve E, Ensom MH (2006) Beyond cyclosporine: a systematic review of limited sampling strategies for other immunosuppressants. Ther Drug Monit 28(3):419\u2013430","journal-title":"Ther Drug Monit"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-018-02613-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-018-02613-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-018-02613-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T01:32:47Z","timestamp":1720920767000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-018-02613-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,14]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["2613"],"URL":"https:\/\/doi.org\/10.1007\/s00228-018-02613-w","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,14]]},"assertion":[{"value":"17 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The research was conducted in accordance with the ethical standards of the Helsinki Declaration. This study protocol was approved by the Ethics Committee of Rui-Jin Hospital, which is affiliated with the Shanghai Jiao-Tong University School of Medicine, and informed consent was obtained from each patient prior to the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}